52-104 Week Off-therapy Second Extension to Study CSPP100A2365

CompletedOBSERVATIONAL
Enrollment

106

Participants

Timeline

Start Date

August 19, 2011

Primary Completion Date

August 3, 2017

Study Completion Date

August 3, 2017

Conditions
Hypertension
Interventions
DRUG

SPP100

Trial Locations (25)

1131

Novartis Investigative Site, Budapest

4400

Novartis Investigative Site, Nyíregyháza

6725

Novartis Investigative Site, Szeged

10016

Novartis Investigative Site, New York

29425

Novartis Investigative Site, Charleston

30721

Novartis Investigative Site, Dalton

39209

Novartis Investigative Site, Jackson

39401

Novartis Investigative Site, Hattiesburg

72202

Novartis Investigative Site, Little Rock

79106

Novartis Investigative Site, Amarillo

83501

Novartis Investigative Site, Lewiston

85107

Novartis Investigative Site, Bratislava

90701

Novartis Investigative Site, Myjava

91701

Novartis Investigative Site, Trnava

97225

Novartis Investigative Site, Portland

35294-0006

Novartis Investigative Site, Birmingham

07227

Novartis Investigative Site, Portland

01010

Novartis Investigative Site, Guatemala City

H-8200

Novartis Investigative Site, Veszprém

03 - 335

Novartis Investigative Site, Warsaw

00907

Novartis Investigative Site, San Juan

03601

Novartis Investigative Site, Martin

08001

Novartis Investigative Site, Prešov

06490

Novartis Investigative Site, Ankara

06500

Novartis Investigative Site, Ankara

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Noden Pharma

INDUSTRY